How is renal artery stenosis suspected, diagnosed, and treated in patients with resistant hypertension?

Renal Artery Stenosis in Resistant Hypertension

Suspect renal artery stenosis in patients with resistant hypertension who have unexplained progressive hypertension, worsening renal dysfunction, or flash pulmonary edema, and initiate medical therapy with thiazide diuretics and calcium channel blockers as first-line treatment, reserving revascularization only for those with progressive disease syndromes despite optimal medical management. 1, 2

Clinical Suspicion and When to Screen

Renal artery stenosis is present in approximately 24% of older patients (mean age 71 years) with resistant hypertension and represents one of the most common secondary causes. 1 You should suspect this diagnosis in the following scenarios:

• Unexplained progressive hypertension despite multiple antihypertensive agents 1
• Progressive renal dysfunction without other clear etiology 1
• Flash pulmonary edema (recurrent episodes of acute pulmonary congestion) 1, 2
• Older patients with atherosclerotic disease elsewhere 1
• Acute rise in creatinine (>30%) after starting ACE inhibitors or ARBs, particularly with volume depletion 1

Most cases are caused by atherosclerotic disease, though fibromuscular dysplasia, renal artery dissection, Takayasu arteritis, and radiation fibrosis are less common causes. 1

Diagnostic Approach

Duplex ultrasound is the most commonly used initial screening modality, identifying increased peak systolic velocity in the renal arteries. 1 The primary imaging modalities include:

• Duplex ultrasound: First-line screening tool 1
• CT angiography: For confirmation before invasive studies 1
• MR angiography: Alternative confirmatory imaging 1
• Selective angiography: Gold standard when intervention is being considered 1, 3

Selection of imaging depends partly on renal function, and investigation is only appropriate when intervention would be carried out if significant stenosis were identified. 1

Medical Management: The Primary Treatment Strategy

Current practice has shifted to optimizing antihypertensive drug therapy as the primary treatment for patients with identified renal artery stenosis before considering revascularization. 1 This represents a fundamental change based on prospective randomized trials demonstrating that moderate renovascular hypertension can be managed medically. 1

First-Line Medical Therapy Components

The European Society of Cardiology recommends a comprehensive medical approach: 2

• Thiazide diuretics at appropriate doses (cornerstone of therapy) 2
• Calcium channel blockers (effective and well-tolerated) 2
• Low-dose aspirin for cardiovascular protection 2
• Statin therapy to address atherosclerotic disease progression 2, 4
• Intense lifestyle modifications including dietary sodium restriction 1, 2

Renin-Angiotensin System Blockers: Use with Caution

ACE inhibitors or ARBs can be added in unilateral renal artery stenosis but must be avoided in bilateral disease. 1, 2 Critical considerations:

• Contraindicated in bilateral renal artery stenosis due to risk of acute renal failure 1, 2
• 10-20% of patients develop unacceptable rise in serum creatinine, particularly with volume depletion 1
• Monitor serum creatinine and potassium levels closely 2
• The creatinine rise is often transient and related to sluggish renal autoregulation when blood pressure falls 1
• Most patients tolerate these medications without adverse renal effects 1
• Patients who experience creatinine rise usually tolerate restarting the medication after successful revascularization 1

When to Consider Revascularization

Revascularization should be reserved for specific high-risk clinical scenarios where patients fail medical therapy or develop progressive disease syndromes. 1, 2 These include:

Absolute Indications for Revascularization

• Flash pulmonary edema (recurrent, unexplained congestive heart failure) 1, 2, 5
• Refractory/resistant hypertension despite maximal medical therapy 1, 2, 5, 6
• Progressive decline in renal function 1, 2
• Fibromuscular dysplasia (angioplasty alone is treatment of choice with high success rates) 2, 5

Evidence Supporting Selective Revascularization

While large randomized trials (including CORAL) failed to show superiority of revascularization over medical therapy alone, these trials had significant limitations and excluded high-risk patients. 3, 5, 7 Importantly:

• Post hoc analysis of CORAL suggests mortality benefit of revascularization in patients without proteinuria 1
• Observational series repeatedly demonstrate that blood pressure control and mortality improve substantially after successful revascularization in selected patients 1, 8, 5, 6
• The best predictor of effective blood pressure reduction after revascularization is a short duration of hypertension 1, 2

Revascularization Methods

• Angioplasty alone for fibromuscular dysplasia (first-line treatment) 2
• Angioplasty with stenting for atherosclerotic disease (procedural success rates 96-100%) 2, 4
• Restenosis develops in 15-24% of treated patients 1, 2
• Procedures should be performed in experienced centers 2

Outcomes and Realistic Expectations

Revascularization rarely cures hypertension (only 9-16% achieve cure defined as DBP ≤90 mmHg off medications) but can improve blood pressure control and reduce medication burden. 2 Among patients with impaired baseline renal function undergoing stenting: 2

• 26% improve
• 48% stabilize
• 26% deteriorate

In patients with true resistant hypertension and atherosclerotic renal artery stenosis, angioplasty significantly decreased daytime ambulatory blood pressure by 14.0/6.4 mmHg and reduced antihypertensive medications from 4.0 to 3.6 drugs. 6

Critical Pitfalls to Avoid

• Never use ACE inhibitors or ARBs in bilateral renal artery stenosis without careful consideration of the risks 1, 2
• Do not pursue revascularization in asymptomatic, incidentally found renal artery stenosis 4
• Bilateral lesions are particularly challenging with considerable risks both with and without intervention 1
• Patient selection is critical for revascularization to maximize potential benefits 3, 5
• All patients require guideline-directed medical therapy regardless of whether revascularization is performed 4